Loading ranking
Loading ranking
11 healthcare stocks, ranked by Traeva's score out of 100 as of 2026-09-28. Intuitive Surgical Inc (ISRG) leads at 97/100. Scores combine four measurements: how far the trading multiple sits from what the company's own fundamentals predict, the direction of revenue and cash flow, margin quality, and balance-sheet risk. The score describes the present, not a forecast.
Updated · 11 companies covered in total
| # | Company | Score | 1yr | Rating |
|---|---|---|---|---|
| 1 | ISRGIntuitive Surgical Inc | 97 | -25% | strong buy |
| 2 | ZTSZoetis Inc | 93 | -57% | strong buy |
| 3 | GEHCGE HealthCare Technologies Inc. | 78 | -6% | buy |
| 4 | ADMAADMA Biologics Inc | 64 | -53% | buy |
| 5 | RXRXRecursion Pharmaceuticals Inc | 62 | -11% | buy |
| 6 | JNJJohnson & Johnson | 51 | +81% | neutral |
| 7 | HIMSHims Hers Health Inc | 50 | -48% | neutral |
| 8 | UNHUnitedHealth Group Incorporated | 42 | +23% | neutral |
| 9 | AAgilent Technologies Inc | 37 | +38% | neutral |
| 10 | NVONovo Nordisk A/S | 37 | -41% | neutral |
| 11 | BWAYBrainsway Ltd | 31 | +128% | avoid |
Each company links through to a full report showing the four factor scores and how the valuation gap was measured.
Each company is scored from 0 to 100 on four factors: valuation lag, which measures how far the current trading multiple sits from the multiple a regression on the company's own fundamentals predicts; trajectory, the direction and consistency of revenue, operating income and free cash flow; structural quality, meaning margin level and stability; and balance-sheet risk, where leverage and weak coverage subtract. The four are combined into one headline number, and all four are published separately on each company's report.
Scores are recomputed daily from the latest filings and market data, and this page is rebuilt hourly. Most movement comes from price, since fundamentals only change when a company reports, which is roughly once a quarter.
No. Traeva publishes quantitative research, not investment advice, and is not a registered investment adviser. A high score means a company currently measures well on four specific factors. It is not a price target, it does not account for anything outside the financial statements, and a valuation gap can persist for years or close because the fundamentals fell to meet the price rather than the price rising to meet them.